medicure medicure achieved a ranking as a  tsx venture  company learn more medicure focuses on acute care hospital products learn more fda approvesaggrastat hdb the highdose bolus hdb dosing regimen has been added to the aggrastat tirofiban hci prescribing information learn more medicure is traded on tsx venture mph the company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug aggrastat tirofiban hci presentation investor information signup for our emails news releases and investment information click here aggrastat aggrastat® is medicures leading speciality pharmaceutical product investor news   latest news july   medicure closes acquisition of additional interests in apicore july   medicure exercises option to acquire additional interests in apicore july   medicure provides update on apicore purchase option medicure corporate compliance about us corporate compliance about us management careers board of directors corporate compliance contact us corporate compliance program a message from the ceo dear colleague in keeping with our commitment in maintaining the highest level of integrity and ethical responsibility we have developed the medicure corporate compliance program conducting our business within the boundaries of this program will ensure the successes we realize are accomplished honestly fairly and with the utmost respect for healthcare providers patients and fellow employees the program contains fundamental legal regulatory and ethical guidelines for conducting business at medicure and its us subsidiary medicure pharma it summarizes our compliance infrastructure and policies and serves as a valuable resource for employees or others with compliance questions or concerns a culture of compliance cannot be realized without the commitment and recognition by each employee of their role in fulfilling our compliance mission with your help we can achieve our business objectives while maintaining our integrity and enhancing our reputation as an ethical leader in the pharmaceutical industry albert friesen phd ceo medicure inc mission statement the medicure corporate compliance program has been designed to ensure that medicure and its us subsidiary medicure pharma conducts business with the highest level of awareness training commitment and adherence to applicable laws and regulations to do so requires the implementation of policies and procedures that address potential compliance risk areas as well as identifiable mechanisms for reporting investigating monitoring and correcting cases of suspected noncompliance the medicure corporate compliance program has been developed in accordance with the requirements and guidelines set forth in the department of health and human services dhhs office of inspector general oig compliance guidance further information and disclosures with respect to specific state compliance laws within the united states can be found in appendix a medicure and its subsidiaries do not have any sales activity outside of the united states compliance organization medicure has developed a compliance infrastructure designed to ensure accountability for legal and ethical responsibilities across the company the compliance infrastructure is comprised of the chief compliance officer and other compliance representation from various functional areas within or as external consultants to the company who all participate as members of the compliance committee cc i chief compliance officer the medicure corporate compliance program operates under the direction of the chief compliance officer the chief compliance officer serves as the chair of the compliance committee cc and has primary responsibility for implementation and oversight of the corporate compliance program the chief compliance officer may enlist support from internal or external resources to assist himher with the implementation of the program the chief compliance officer provides annual or more frequent substantive compliance updates to the board of directors and the ceo other responsibilities of the chief compliance officer or his or her designees include making periodic revisions to the corporate compliance program in light of any regulatory legal or organizational changes requiring such revisions coordinating and ensuring employees undergo the essential compliance training developing open communication channels to encourage employees to inquire about or report compliance issues without fear of retribution overseeing internal investigations and any corresponding corrective actions directing monitoring and auditing efforts to ensure compliance with laws regulations and policies and providing the necessary periodic declarations or certifications relative to applicable compliance requirements ii compliance committee cc the cc has been established to advise and assist the chief compliance officer and hisher designees in the implementation and oversight of the corporate compliance program the cc will convene on a quarterly basis to update and review compliance issues the cc is composed of senior representatives from various functions and disciplines within or as consultants to the company policies and procedures it is the responsibility of the chief compliance officer and his or her designees in conjunction with the cc to create revise and communicate policies and procedures that address areas of potential compliance risk within the company these policies shall be reviewed periodically and updated as necessary to reflect regulatory legal or organizational changes these policy reviews as well as the requisite training and education either initially or as updated shall be performed by the respective compliance function or discipline within the organization the company has adopted core compliance policies that provide the prevailing principles to help ensure that we conduct our business affairs with honesty and integrity and in full compliance with all applicable laws rules and regulations in addition all employees are required to familiarize themselves with and adhere to all company standards policies and procedures that apply in the areas within the scope of their work responsibilities hard copy versions of all policies or procedures falling under the corporate compliance program are maintained within the respective compliance disciplines electronic versions of these policies will also be available to affected employees through an internal database compliance training and education an effective education and training program is an integral part of the corporate compliance program employees will be required to participate in compliancerelated training designated by the chief compliance officer or by another function or discipline within the organization our compliance education and training programs are designed with the following objectives to educate employees on their ethical and legal obligations in reference to applicable federal health care program requirements to encourage a culture of compliance within the organization and ensure that employees understand their role in the compliance process and to promote knowledge of and compliance with corporate policies and procedures and relevant federal state and local laws and regulations to communicate industry standards and governmental requirements while providing a means for the quick identification and resolution of compliance issues to understand the consequences of failing to comply with the presented comprehensive compliance program in addition the company regularly reviews and updates the training program where new updates are needed as well as identifying additional areas that need to be addressed compliance questions and concerns situations which involve concerns about conflicts of interest violations or suspected violations of laws rules policies regulations or this corporate compliance program may not always be clear and may require complex judgment a compliance help line has been established for any employee to call with questions about compliance or to report a suspected violation of policy the help line is a tollfree number that is available  hours a day  days a week the help line is administered on medicures behalf by an independent third party whose employees are specially trained at collecting pertinent information the help line administrator will summarize the calls and send reports to the chief compliance officer or hisher designee within one business day individuals are also encouraged to be open and candid in discussing any compliance issues with their manager reporting compliance concerns all employees are required to report any concerns about conflicts of interest violations or suspected violations of laws rules policies regulations or this corporate compliance program you may report any such concerns to the compliance help line at   confidentiality on calls made to the compliance help line employees have the option of providing their identification or making an anonymous report its important that employees have confidence and trust in the company in knowing that all efforts will be made to conceal the identity of the caller and the report being made to the extent possible when investigating the matter no retaliation policy every employee has the responsibility to report to the company any suspected violation of law or policy by another employee or agent of the company employees can report such violations without fear of retribution or retaliation employees who threaten retaliate against or harass any person who has reported a compliance concern shall be subject to disciplinary action up to and including termination investigations and corrective action an essential goal of the corporate compliance program is to identify these unethical or unlawful policy violations and to take appropriate corrective actions in order to punish and further prevent these violations we foster a culture in which problems and concerns relating to compliance are brought to light investigated and remediated we are committed to investigating and addressing any reports of suspected policy violations while seeking to ensure that all reported violations are handled in a uniform and evenhanded manner and in a manner designed to promote compliance with company policies monitoring and auditing a key aspect to the corporate compliance program is periodic monitoring and auditing of employee compliance with policies and procedures to assess whether elements of the corporate compliance program have been satisfied for example assessments may include whether for a defined risk area standards have been developed dissemination and training around these standards have been conducted a mechanism for determining adherence to these standards is in place an investigation into alleged misconduct was commenced and appropriate corrective action if any has been taken the monitoring and auditing plan is reasonably designed to detect violations by an organizations employees or agents the monitoring and auditing plan will also maintain and enhance the effectiveness of internal controls by assessing changes to laws regulations or business activities affecting the company recordkeeping and retention unless otherwise specified records pertaining to the implementation and maintenance of the corporate compliance program shall be maintained with the chief compliance officer in the corporate compliance program files in some cases training records and other compliance documents will be maintained within the specific compliance function or discipline appendix a state compliance lawsi california medicure has developed its corporate compliance program in accordance with the compliance program guidance for pharmaceutical manufacturers published by the office of inspector general us department of health and human services oig guidance and the california health and safety code part  division  §  medicure has adopted written policies and procedures to help ensure that we conduct our business affairs with honesty and integrity and in full compliance with all applicable laws rules and regulations to this end medicure has adopted the phrma code as its marketing code of conduct for our employees conducting business in the state of california the specific annual dollar limit that medicure has placed on items or activities provided to a healthcare professional in california is  compliance declaration to the best of our knowledge and based upon our good faith understanding of the statutory requirements of sb  we are in compliance with the basic established elements of the oig compliance guidance and with our corporate compliance program as published on our public website at wwwmedicurecomcompliance copies of the medicure corporate compliance program can also be obtained by calling   ii nevada medicure has adopted written policies and procedures to help ensure that we conduct our business affairs with honesty and integrity and in full compliance with all applicable laws rules and regulations to this end medicure has adopted the phrma code as its marketing code of conduct for any future employees we may have conducting business in the state of nevada currently medicure does not have any employees conducting business in the state of nevada iii massachusetts medicure does not currently employ or contract with a pharmaceutical or medical device manufacturer agent in the state of massachusetts medicure investors investors corporate governance overview corporate presentation corporate governance latest news all news  news releases archieve  news releases  news releases news prior to  listed on sedarcom analyst coverage andre uddin mackie research sheila broughton pi financial steven salz m  partners more info contact investor relations irmedicurecom  ext  corporate governance charters audit  finance charter executive compensation nominating and corporate governance committee charter code of ethics code of ethics whistleblower policy shareholder information auditors ernst  young commodity exchange tower main streetrc g winnipeg transfer agent computershare investor services inc  th avenue swcalgary alberta tp s investor relations  public inquiries irmedicurecom ext  medicure news news  all news latest news all news  news releases archieve  news releases  news releases   april  medicure reports financial results for the first quarter of   april  medicure q results and conference call dates  april medicure announces approval of expanded dosing time for aggrastat®  april medicure to present at the  bloom burton  co healthcare conference  april  medicure reports financial results for the seven months ended december    march  medicure announces grant of options  march  medicure announces issuance of shares under previously announced shares for debt settlement  february  medicure provides quarterly revenue on a calendar basis following change to year end  january medicure announces shares for debt settlements     december medicure announces change in fiscal year end and provides onetime guidance on quarterly revenue  november dr albert friesen to file early warning report  october medicure reports financial results for the first quarter fiscal   september medicure reports financial results for fiscal   august medicure provides update on tardoxal and tendtd study  july medicure announces shares for debt settlement  july medicure announces grant of options  july medicure acquires minority position in pharmaceutical manufacturer apicore  april medicure comments on recent trading activity  april medicure engages knight therapeutics inc to provide advisory services  march medicure reports third quarter financial results for fiscal   january medicure reports second quarter results for fiscal    october medicure reports first quarter financial results for fiscal   october medicure announces approval for recommended dosing regimen for aggrastat®  september  medicure reports financial results for fiscal   april medicure reports third quarter financial results for fiscal   february  dr albert d friesen to file early warning report  january  medicure reports second quarter financial results for fiscal   january medicure appoints brent fawkes to board of directors  january medicure announces filing of snda for aggrastat label change medicure generic products in development generic products business development generic products tardoxal apicore generic products as announced on january   medicure has initiated the development of a highvalue cardiovascular generic drug the project is a collaboration between medicure international inc and apicore us llc the collaborative project is focused on the development of an intravenous abbreviated new drug application anda drug product for an acute cardiovascular indication medicure and apicore have entered into an exclusive product supply and development agreement under which medicure holds all commercial rights medicure announced on december   the filing of the anda with the us food and drug administration medicure is currently developing additional anda opportunities focusing on acute care cardiovascular injectables for the us hospital market medicure about medicure about us medicure about medicure management board of directors careers corporate compliance contact us about medicure medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the us hospital market medicure’s vision is to become a leading specialty pharmaceutical company that improves the lives of patients while delivering value for its shareholders the company’s current focus is in the area of acute cardiovascular care a market served by its commercial product aggrastat tirofiban hcl the company is also looking to develop and acquire additional hospital products to accomplish this the company is leveraging its historical expertise in clinical development as well as exploring acquisition opportunities with growth potential medicure was established in  and spent its first decade focused on research and development in  the company began a transition to focus on its commercial specialty pharmaceutical business this new direction was solidified in october  with the us fda approval of the new label for aggrastat the label change has provided a basis for the company to grow sales and achieve profitability and also to pursue development and acquisition opportunities medicure’s board and management is committed to building value for its existing shareholder base and is patiently pursuing a longterm view to establishing the company as a leading international pharmaceutical company  one that is distinguished by its unique fit within the contemporary market medicure inc is based in winnipeg canada and publicly traded on the toronto stock exchange venture under the symbol mph its subsidiaries include medicure international inc barbados which owns the us rights to aggrastat as well as two us corporations medicure usa inc and medicure pharma inc which distributes the company’s products in the united states medicure inc and medicure usa have a minority interest and fixed option to acquire the holding companies of apicore llc and apicore us llc collectively apicore apicore is a developer and manufacturer of specialty active pharmaceutical ingredients apis and generic products andas for more information about medicure and the risks and uncertainties involved in its business please refer to the most recent management discussion and analysis and in the risk factors section of its most recent form f medicure inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports medicure inc  product pipeline review   medicure inc  product pipeline review   wgr  june  global  pages global markets direct description table of content sample report enquiry before buy related reports medicure inc  product pipeline review  summaryglobal markets direct’s ‘medicure inc  product pipeline review  ’ provides an overview of the medicure inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of medicure inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of medicure inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of medicure inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the medicure inc’s pipeline productsreasons to buy evaluate medicure inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of medicure inc in its therapy areas of focus identify new drug targets and therapeutic classes in the medicure inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of medicure inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of medicure inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of medicure inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures medicure inc snapshot medicure inc overview key information key facts medicure inc  research and development overview key therapeutic areas medicure inc  pipeline review pipeline products by stage of development pipeline products  monotherapy medicure inc  pipeline products glance medicure inc  clinical stage pipeline products phase ii productscombination treatment modalities medicure inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities medicure inc  drug profiles tardoxal product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress tirofiban hydrochloride transdermal product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress medicure inc  pipeline analysis medicure inc  pipeline products by target medicure inc  pipeline products by route of administration medicure inc  pipeline products by molecule type medicure inc  pipeline products by mechanism of action medicure inc  recent pipeline updates medicure inc  dormant projects medicure inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesmedicure inc key information medicure inc key facts medicure inc  pipeline by indication  medicure inc  pipeline by stage of development  medicure inc  monotherapy products in pipeline  medicure inc  phase ii  medicure inc  preclinical  medicure inc  discovery  medicure inc  pipeline by target  medicure inc  pipeline by route of administration  medicure inc  pipeline by molecule type  medicure inc  pipeline products by mechanism of action  medicure inc  recent pipeline updates  medicure inc  dormant developmental projects medicure inc subsidiaries list of figuresmedicure inc  pipeline by top  indication  medicure inc  pipeline by stage of development  medicure inc  monotherapy products in pipeline  medicure inc  pipeline by top  target  medicure inc  pipeline by top  route of administration  medicure inc  pipeline by top  molecule type  medicure inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send medicure inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report medicure inc  product pipeline review   published by global markets direct product code  published june   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license medicure inc  product pipeline review   published june   content info  pages description global markets directs medicure inc  product pipeline review   provides an overview of the medicure incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of medicure incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of medicure inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of medicure incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the medicure incs pipeline products reasons to buy evaluate medicure incs strategic position with total access to detailed information on its product pipeline assess the growth potential of medicure inc in its therapy areas of focus identify new drug targets and therapeutic classes in the medicure incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of medicure inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of medicure inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of medicure inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures medicure inc snapshot medicure inc overview key information key facts medicure inc  research and development overview key therapeutic areas medicure inc  pipeline review pipeline products by stage of development pipeline products  monotherapy medicure inc  pipeline products glance medicure inc  clinical stage pipeline products phase ii productscombination treatment modalities medicure inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities medicure inc  drug profiles tardoxal product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress tirofiban hydrochloride transdermal product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress medicure inc  pipeline analysis medicure inc  pipeline products by target medicure inc  pipeline products by route of administration medicure inc  pipeline products by molecule type medicure inc  pipeline products by mechanism of action medicure inc  recent pipeline updates medicure inc  dormant projects medicure inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables medicure inc key information medicure inc key facts medicure inc  pipeline by indication  medicure inc  pipeline by stage of development  medicure inc  monotherapy products in pipeline  medicure inc  phase ii  medicure inc  preclinical  medicure inc  discovery  medicure inc  pipeline by target  medicure inc  pipeline by route of administration  medicure inc  pipeline by molecule type  medicure inc  pipeline products by mechanism of action  medicure inc  recent pipeline updates  medicure inc  dormant developmental projects medicure inc subsidiaries list of figures medicure inc  pipeline by top  indication  medicure inc  pipeline by stage of development  medicure inc  monotherapy products in pipeline  medicure inc  pipeline by top  target  medicure inc  pipeline by top  route of administration  medicure inc  pipeline by top  molecule type  medicure inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved polymed medical devices home company company profile modern manufacturing facilities research  development products infusion therapy safety iv cannula with adva needle technology safety iv cannula quick flashback iv cannula iv cannula needle free connectors three way stop cocks iv infusion sets iv flow regulator extension lines ttype extension set stylemandrin with luer lock injection stopper luer lock injection site safety winged infusion set central venous access catheters central venous catheters cvp manometer anaesthesia suction catheters oxygen mask oxygen mask with reservoir aerosol therapy mask fixed concentration mask nasocath oxygen catheter catheter mount guedel airway respiratory exerciser endotracheal tubes tracheostomy tubes spinal needle gastroenterology ryle’s tube levin’s tube feeding bag infant feeding tube t tube stomach tubes umbilical catheter blood management blood bag systems transfusion pump set safety blood collection set blood administration sets blood bag with safety device  sampling bag cpdsagmtotm bag system top  bottom extraction bag system acd bag urology urine collection bags measured volume meter urine drainage catheters foley balloon catheters tur set irrigation sets surgery  wound drainage closed wound suction units thoracic drainage catheter – straight thoracic drainage catheter – angled thoracic drainage catheter with trocar under water seal drainage system under water seal drainage bottle high pressure vaccum bottles with extension tube abdominal drainage set yankaur suction set yankaur suction handle colostomy bag redon drain dialysis fistula needles haemodialysis catheter peritoneal dialysis set peritoneal dialysis transfusion set haemoline diagnostics blood collection tubes blood collection needle standard needle holder luer adaptor novac unovac pediatrics mucus extractors umbilical cord clamps other insulin syringes sputum collector dry brush quality quality assurance certification contact us reach us feedbackinquiry ⇒ navigatehome – company profile – modern manufacturing facilities – research  development – infusion therapy – – safety iv cannula with adva needle technology – – safety iv cannula – – quick flashback iv cannula – – iv cannula – – needle free connectors – – three way stop cocks – – iv infusion sets – – iv flow regulator – – extension lines – – ttype extension set – – stylemandrin with luer lock – – injection stopper – – luer lock injection site – – safety winged infusion set – central venous access catheters – – central venous catheters – – cvp manometer – anaesthesia – – suction catheters – – oxygen mask – – oxygen mask with reservoir – – aerosol therapy mask – – fixed concentration mask – – nasocath – – oxygen catheter – – catheter mount – – guedel airway – – respiratory exerciser – – endotracheal tubes – – tracheostomy tubes – – spinal needle – gastroenterology – – ryle’s tube – – levin’s tube – – feeding bag – – infant feeding tube – – t tube – – stomach tubes – – umbilical catheter – blood management – – blood bag systems – – transfusion pump set – – safety blood collection set – – blood administration sets – – blood bag with safety device  sampling bag – – cpdsagmtotm bag system – – top  bottom extraction bag system – – acd bag – urology – – urine collection bags – – measured volume meter – – urine drainage catheters – – foley balloon catheters – – tur set – – irrigation sets – surgery  wound drainage – – closed wound suction units – – thoracic drainage catheter – straight – – thoracic drainage catheter – angled – – thoracic drainage catheter with trocar – – under water seal drainage system – – under water seal drainage bottle – – high pressure vaccum bottles with extension tube – – abdominal drainage set – – yankaur suction set – – yankaur suction handle – – colostomy bag – – redon drain – dialysis – – fistula needles – – haemodialysis catheter – – peritoneal dialysis set – – peritoneal dialysis transfusion set – – haemoline – diagnostics – – blood collection tubes – – blood collection needle – – standard needle holder – – luer adaptor – – novac – – unovac – pediatrics – – mucus extractors – – umbilical cord clamps – other – – insulin syringes – – sputum collector – – dry brush quality – quality assurance – certification contact us – reach us – feedbackinquiry user friendly selfactivating safety machanism touching life with care we care as we cure highly trained  experienced personnel modern production facilities  processes quality assurance  certification at polymed our pursuit of excellence is a reflection of our commitment to matters closest to our hearts – such as care concern and love for humanity while our technologies are truly state – of – the – art our business model is state – of – the – heart innovations quality standards products… everything flows forth from our passion to touch life in a meaningful way products range infusion therapy safety iv cannula with adva needle technology safety iv cannula quick flashback iv cannula iv cannula needle free connectors three way stop cocks iv infusion sets iv flow regulator extension lines ttype extension set stylemandrin with luer lock injection stopper luer lock injection site safety winged infusion set central venous access catheters central venous catheters haemodialysis catheter cvp manometer anaesthesia suction catheters oxygen mask oxygen mask with reservoir aerosol therapy mask fixed concentration mask nasocath oxygen catheter catheter mount guedel airway respiratory exerciser endotracheal tubes tracheostomy tubes spinal needle gastroenterology ryle’s tube levin’s tube feeding bag t tube stomach tubes umbilical catheter blood management blood bag systems transfusion pump set safety blood collection set blood administration sets blood bag with safety device  sampling bag cpdsagmtotm bag system top  bottom extraction bag system acd bag urology urine collection bags measured volume meter urine drainage catheters foley balloon catheters tur set irrigation sets surgery  wound drainage closed wound suction units thoracic drainage catheter – straight thoracic drainage catheter – angled thoracic drainage catheter with trocar under water seal drainage system under water seal drainage bottle high pressure vaccum bottles with extension tube abdominal drainage set yankaur suction set yankaur suction handle colostomy bag redon drain dialysis fistula needles haemodialysis catheter peritoneal dialysis set peritoneal dialysis transfusion set diagnostics blood collection tubes blood collection needle standard needle holder luer adaptor novac unovac pediatrics mucus extractors umbilical cord clamps others insulin syringes sputum collector dry brush events isacon  november thth ludhiana stall no a  b asicon  december thth mysuru stall no d  d arab health dubai janfeb  th august  booth no dl miami beach florida th may  boothblue hall street i th november   e  dusseldrof germany poly medicure limited home investor information sitemap catalogue careers news ⇒ navigatehome investor information sitemap catalogue careers news top developed by abacus desk medicure inc product pipeline review  trends share size research report uscanada toll free home global markets direct pharmaceutical medicure inc product pipeline review  medicure inc product pipeline review  published by  global markets direct published date  nov  category  pharmaceutical no of pages   pages description table of content check discount medicure inc product pipeline review  global market directs pharmaceuticals report medicure inc product pipeline review  provides data on the medicure incs research and development focus the report includes information on current developmental pipeline complete with latest updates and features on discontinued and dormant projects  this report is built using data and information sourced from global markets directs proprietary databases medicure incs corporate website sec filings investor presentations and featured press releases both from medicure inc and industryspecific third party sources put together by global markets directs team  scope medicure inc brief medicure inc overview including business description key information and facts and its locations and subsidiaries review of current pipeline of medicure inc human therapeutic division overview of pipeline therapeutics across various therapy areas coverage of current pipeline molecules in various stages of drug development including the combination treatment modalities across the globe product profiles for late stage and clinical stage products of medicure inc with complete description of the products developmental history mechanism of action therapeutic class target and major milestones  recent updates of the medicure incs pipeline in the last quarter  key discontinued and dormant projects  latest news and deals relating to the products reasons to buy evaluate medicure incs strategic position with total access to detailed information on its product pipeline  assess the growth potential of medicure inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the medicure incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  exploit collaboration and partnership opportunities with medicure inc  avoid intellectual property rights related issues  explore the dormant and discontinued projects of medicure inc and identify potential opportunities in those areas table of contents table of contents list of tables list of figures medicure inc snapshot medicure inc overview key information key facts medicure inc research and development overview key therapeutic areas medicure inc pipeline review pipeline products by stage of development pipeline products monotherapy medicure inc pipeline products glance medicure inc clinical stage pipeline products phase ii productscombination treatment modalities medicure inc early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities medicure inc drug profiles mc product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress mc product description mechanism of action rd progress pyridoxal  phosphate product description mechanism of action rd progress tirofiban hydrochloride transdermal formulation product description mechanism of action rd progress medicure inc pipeline products by route of administration medicure inc pipeline products by mechanism of action medicure inc recent pipeline updates medicure inc  dormant projects medicure inc locations and subsidiaries head office medicure inc recent developments medicure inc press release jan   medicure provides update on tendtd phase ii clinical trial mar   medicure inc announces regulatory approval of a phase ii clinical trial of avastrem for the treatment of tardive dyskinesia medicure inc announces regulatory approval of a phase ii clinical trial of avastrem for the treatment o jan   medicure announces regulatory approval of a phase ii clinical trial of avastrem for the treatment of tardive dyskinesia financial deals landscape medicure inc deals summary medicure inc pharmaceuticals  healthcare deal details asset transactions medicure acquires us rights to aggrastat from mgi pharma equity offering medicure announces private placement of  million medicure completes private placement of  million medicure completes private placement of  million medicure completes public offering of  million  appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer  list of table medicure inc key information medicure inc key facts medicure inc pipeline by indication  medicure inc pipeline by stage of development  medicure inc monotherapy products in pipeline  medicure inc phase ii  medicure inc preclinical  medicure inc discovery  medicure inc pipeline by route of administration  medicure inc pipeline products by mechanism of action  medicure inc recent pipeline updates  medicure inc  dormant developmental projects medicure inc deals summary medicure acquires us rights to aggrastat from mgi pharma medicure announces private placement of  million medicure completes private placement of  million medicure completes private placement of  million medicure completes public offering of  million  list of chart medicure inc pipeline by indication  medicure inc pipeline by stage of development  medicure inc monotherapy products in pipeline  medicure inc pipeline by route of administration  medicure inc  pipeline products by mechanism of action   make an enquiry before buying this report please fill the enquiry form below full name  your email  job title  company  phone no  pls affix country code message security code   choose license type  select user license single license user  multiple license user  do you wish to check sample of this report order a sample report have query on this report related news grab gets us bn funding from didi and softbank google street view introduces international space station view zinc prices to continue to shoot as hopes of output rise remain bleak shift to cloudbased products and services fares well for microsoft india remains leading provider of online labors in technology and software development sector research assistance we will be happy to help you find what you need please call us or write to us  uscanada toll free tel   email  salesresearchmozus market report medicure inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing medicure inc  product pipeline review   jun    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs medicure inc  product pipeline review   provides an overview of the medicure incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of medicure incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of medicure inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of medicure incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the medicure incs pipeline productsreasons to buyevaluate medicure incs strategic position with total access to detailed information on its product pipelineassess the growth potential of medicure inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the medicure incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of medicure inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of medicure incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of medicure inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresmedicure inc snapshotmedicure inc overviewkey informationkey factsmedicure inc  research and development overviewkey therapeutic areasmedicure inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapymedicure inc  pipeline products glancemedicure inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesmedicure inc  early stage pipeline productspreclinical productscombination treatment modalitiesdiscovery productscombination treatment modalitiesmedicure inc  drug profilestardoxalproduct descriptionmechanism of actionrd progressmcproduct descriptionmechanism of actionrd progressmcproduct descriptionmechanism of actionrd progresstirofiban hydrochloride transdermalproduct descriptionmechanism of actionrd progressmcproduct descriptionmechanism of actionrd progressmcproduct descriptionmechanism of actionrd progressmedicure inc  pipeline analysismedicure inc  pipeline products by targetmedicure inc  pipeline products by route of administrationmedicure inc  pipeline products by molecule typemedicure inc  pipeline products by mechanism of actionmedicure inc  recent pipeline updatesmedicure inc  dormant projectsmedicure inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesmedicure inc key informationmedicure inc key factsmedicure inc  pipeline by indication medicure inc  pipeline by stage of development medicure inc  monotherapy products in pipeline medicure inc  phase ii medicure inc  preclinical medicure inc  discovery medicure inc  pipeline by target medicure inc  pipeline by route of administration medicure inc  pipeline by molecule type medicure inc  pipeline products by mechanism of action medicure inc  recent pipeline updates medicure inc  dormant developmental projectsmedicure inc subsidiarieslist of figuresmedicure inc  pipeline by top  indication medicure inc  pipeline by stage of development medicure inc  monotherapy products in pipeline medicure inc  pipeline by top  target medicure inc  pipeline by top  route of administration medicure inc  pipeline by top  molecule type medicure inc  pipeline products by top  mechanism of action  companies mentioned in this reportmedicure inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc medicure inc  company profile from hoover’s  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  profile company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports medicure inccompany information  waverley st suite winnipeg mb rt c canada  † httpwwwmedicurecom top  competitors pfizer inc astrazeneca plc arena pharmaceuticals inc unlock more access to hoover’s build customized email lists  based on your best customer profile learn more about the companies you want to sell to hoover’s has reports on  million companies and  industries  data points are updated each day get real insight written by real people – exclusive research and reviews by our inhouse editorial staff we can deliver our data to your desktop to excel direct to your crm into your custom app or via mobile request your free trial call   today to get started with a free trial   medicure inc company profile medicure develops drugs for the treatment of cardiovascular diseases and stroke its first commercial product aggrastat is an injectable treatment for acute coronary syndrome medicure is seeking partnerships to expand its product portfolio in late  the company acquired a majority stake in apicore which develops and manufactures specialty active pharmaceutical ingredients apis and pharmaceuticals that acquisition added two manufacturing facilities  one in new jersey and another in india medicure was established in  † some telephone numbers on the hoover’s site may be on a country’s do not call or do not contact list including but not limited to the united kingdom’s ctps or tps registers it is a legal requirement that companies do not make sales or marketing calls to registered numbers these are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls by using the information provided on the hoover’s sites as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local state national or international laws and regulations including any local do not call registers or marketing regulations and agree to defend indemnify and hold harmless dun  bradstreet and each of its affiliates in the event your use violates such laws and regulations additional medicure inc information sales preparation get relevant industry context to prepare for your next sales call – trends competitors news call prep questions and more marketing campaigns find prospect companies that meet the profile of your best customers to maximize campaign roi strategy  planning identify new market opportunities and new strategies for existing markets credit management  finance determine and track a company’s financial condition related tags winnipeg mb canada pharmaceutical manufacturing free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days medicure inc  revenue and financial reports  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  revenue  financial data company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports medicure inc revenue and financial data medicure develops drugs for the treatment of cardiovascular diseases and stroke its first commercial product aggrastat is an injectable treatment for acute coronary syndrome medicure is seeking partnerships to expand its product portfolio in late  the company acquired a majority stake in apicore which develops and manufactures specialty active pharmaceutical ingredients apis and pharmaceuticals that acquisition added two manufacturing facilities  one in new jersey and another in india medicure was established in  financials information for medicure inc track this company’s financial condition view company report request your free trial income statement cash flowbalance sheetcredit rating income statement mil      revenue      gross profit      operating income      net income      diluted eps      cash flow mil    cash at the beginning of the year    net operating cash    net investing cash    net financing cash    net change in cash    cash at end of the year    capital expenditure    assets mil    current assets cash    net receivables    inventories    other income assets    asset summary total current assets    net fixed assets    other noncurrent assets    total assets    liabilities mil    current liabilities accounts payable    short term debt    other current liabilities    liability summary total current liabilities    long term debt    other noncurrent liabilities    total liabilities    stakeholders equity mil    equity preferred stock equity    common stock equity    equity summary total equity    shares outstanding    credit rating high these businesses have a high projected rate of delinquency or a high failure risk need to go deeper no problem save time with complex financial data at your fingertips access financial statements sec filings earnings estimates and more call   to talk to a business information consultant request your free trial   free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days medicure inc mphv key developments  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states medicure inc mphv related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse mphv on tsx venture exchange cad pm edt change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  latest key developments source significant developments medicure exercises option to acquire additional interests in apicore monday  jul  pm edt  july  reuters  medicure inc medicure exercises option to acquire additional interests in apicoremedicure  option exercise allows for acquisition of all of shares of apicore held by founding shareholders for  millionacquisition brings medicures ownership in apicore inc to about  percent  percent on a fully diluted basismedicure  additionally apicore has repaid  million secured loan previously provided to apicore by medicure that was announced on january   full article medicure qtrly loss per share c wednesday  may  pm edt  may  reuters  medicure inc medicure reports financial results for quarter ended march  quarterly loss per share cquarterly revenue rose  percent to c million  full article medicure announces fda approval for apicores generic tetrabenazine thursday  mar  am edt   medicure announces fda approval for apicores generic tetrabenazine medicure inc  its unit has received final approval from fda for cos anda for tetrabenazine tablets in  mg and  mg strengths  full article medicure announces filing of anda in collaboration with apicore tuesday  dec  pm est  medicure inc  medicure announces filing of anda in collaboration with apicore  co and apicore have entered into an exclusive product supply and development agreement under which medicure holds all commercial rights medicure owns a majority interest in apicore as well as an option to acquire remaining issued shares of apicore until july   full article medicure exercises option to acquire majority interest in apicore friday  nov  am est  medicure inc  medicure inc continues to have option rights until july   to acquire additional shares in apicore  medicure  allowing for acquisition of  million series a preferred shares  million warrants for  millionbringing cos ownership in apicore to  percent medicure exercises option to acquire majority interest in apicore  full article medicure fda approves new aggrastat product format thursday  sep  am edt  medicure inc  fda approves new aggrastat® product format commercial release of bolus vial will take place at beginning of q of this year  full article medicure reports q earnings per share  wednesday  aug  pm edt  medicure inc  medicure reports second quarter  financial results  qtrly earnings per share  says net revenue of  million during the quarter ended june   up  pct compared to  million last year  full article medicure inc qtrly earnings per share  wednesday  may  pm edt  medicure inc  says recorded net revenue of  million during quarter ended march   an increase of   qtrly earnings per share  medicure reports first quarter  financial results  full article medicure says coo dawson reimer will leave the company monday  may  pm edt  medicure inc  employment agreement with president and chief operating officer dawson reimer  has been terminated effective immediately  friesen founder of medicure will in addition to his current responsibilities take on role of president of company medicure announces departure of president and chief operating officer  full article medicure inc announces anda collaboration with apicore wednesday  jan  am est  medicure incsays has initiated development of a highvalue cardiovascular generic drugproject is a collaboration between medicure international inc and apicore us llcco and apicore have entered into an exclusive product supply and development agreement under which medicure holds all commercial rightssays companies anticipate filing the anda with us food and drug administration by the end of   full article previous next medicure inc news briefmedicure exercises option to acquire additional interests in apicore  medicure exercises option to acquire additional interests in apicore » more mphv news earnings vs estimates » more financials related topics stocksstock screenermarket datahealthcarepharmaceuticals